C4 Therapeutics Statistics

Total Valuation

C4 Therapeutics has a market cap or net worth of $99.41 million. The enterprise value is -$70.93 million.

Market Cap	99.41M
Enterprise Value	-70.93M

Important Dates

The next estimated earnings date is Thursday, July 31, 2025, before market open.

Earnings Date	Jul 31, 2025
Ex-Dividend Date	n/a

Share Statistics

C4 Therapeutics has 71.01 million shares outstanding. The number of shares has increased by 28.41% in one year.

Current Share Class	71.01M
Shares Outstanding	71.01M
Shares Change (YoY)	+28.41%
Shares Change (QoQ)	+0.32%
Owned by Insiders (%)	3.65%
Owned by Institutions (%)	72.72%
Float	49.73M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.53
Forward PS	5.77
PB Ratio	0.52
P/TBV Ratio	0.51
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 5.70, with a Debt / Equity ratio of 0.33.

Current Ratio	5.70
Quick Ratio	5.47
Debt / Equity	0.33
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -45.55% and return on invested capital (ROIC) is -24.80%.

Return on Equity (ROE)	-45.55%
Return on Assets (ROA)	-20.30%
Return on Invested Capital (ROIC)	-24.80%
Return on Capital Employed (ROCE)	-41.82%
Revenue Per Employee	$361,664
Profits Per Employee	-$938,882
Employee Count	110
Asset Turnover	0.11
Inventory Turnover	n/a

Taxes

In the past 12 months, C4 Therapeutics has paid $131,000 in taxes.

Income Tax	131,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -69.76% in the last 52 weeks. The beta is 2.94, so C4 Therapeutics's price volatility has been higher than the market average.

Beta (5Y)	2.94
52-Week Price Change	-69.76%
50-Day Moving Average	1.49
200-Day Moving Average	3.40
Relative Strength Index (RSI)	44.55
Average Volume (20 Days)	1,359,424

Short Selling Information

The latest short interest is 6.38 million, so 8.98% of the outstanding shares have been sold short.

Short Interest	6.38M
Short Previous Month	6.17M
Short % of Shares Out	8.98%
Short % of Float	12.82%
Short Ratio (days to cover)	6.29

Income Statement

In the last 12 months, C4 Therapeutics had revenue of $39.78 million and -$103.28 million in losses. Loss per share was -$1.48.

Revenue	39.78M
Gross Profit	-75.39M
Operating Income	-116.56M
Pretax Income	-106.59M
Net Income	-103.28M
EBITDA	-114.73M
EBIT	-116.56M
Loss Per Share	-$1.48

Full Income Statement

Balance Sheet

The company has $215.09 million in cash and $64.37 million in debt, giving a net cash position of $170.34 million or $2.40 per share.

Cash & Cash Equivalents	215.09M
Total Debt	64.37M
Net Cash	170.34M
Net Cash Per Share	$2.40
Equity (Book Value)	195.14M
Book Value Per Share	2.75
Working Capital	191.72M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$80.32 million and capital expenditures -$180,000, giving a free cash flow of -$80.50 million.

Operating Cash Flow	-80.32M
Capital Expenditures	-180,000
Free Cash Flow	-80.50M
FCF Per Share	-$1.13

Full Cash Flow Statement

Margins

Gross margin is -189.51%, with operating and profit margins of -292.99% and -259.60%.

Gross Margin	-189.51%
Operating Margin	-292.99%
Pretax Margin	-259.27%
Profit Margin	-259.60%
EBITDA Margin	-288.40%
EBIT Margin	-292.99%
FCF Margin	n/a

Dividends & Yields

C4 Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-28.41%
Shareholder Yield	-28.41%
Earnings Yield	-103.89%
FCF Yield	-80.98%

Analyst Forecast

The average price target for C4 Therapeutics is $12.00, which is 757.14% higher than the current price. The consensus rating is "Buy".

Price Target	$12.00
Price Target Difference	757.14%
Analyst Consensus	Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	114.32%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

C4 Therapeutics has an Altman Z-Score of -1.57 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.57
Piotroski F-Score	4